Impact of p53-based immunization on primary chemically-induced tumors

International Journal of Cancer

Volumn 113, Issue 6, 2005, Pages 961-970

  Cicinnati, Vito R ^a   Dworacki, Grzegorz ^a   Albers, Andreas ^a   Beckebaum, Susanne ^b   Tüting, Thomas ^a   Kaczmarek, Elzbieta ^c   DeLeo, Albert B ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Immune evasion; Methylcholanthrene; Mouse sarcomas; p53; Vaccine

Indexed keywords

3 METHYLCHOLANTHRENE; CARCINOGEN; CD3 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; EPITOPE; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLASMID DNA; POLYCYCLIC HYDROCARBON; PROTEIN P53; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; GENOTYPE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; BASE SEQUENCE; CANCER VACCINES; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SURVIVAL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 11844289015     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20686     Document Type: Article

References (41)

1. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci USA 1979;76:2420-4.
2. Harris CC. Structure and function of the p53 tumor suppressor gene: clues and rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
3. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science (Washington DC) 1991;253:49-53.
4. Houbiers JG, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993;9:2072-7.
5. Röpke M, Hald J, Guldenberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, van der Burg S, Nijman HW, Melief CJM, Claesson MH. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996;93:14704-7.
6. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
7. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995;92:11993-7.
8. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996;183:1357-65.
9. DeLeo AB. P53-based immunotherapy of cancer. Crit Rev Immunol 1998;18:29-35.
10. Sogn J. Tumor immunology: The glass is half full. Immunity 1998;8:757-63.
11. Lollini PL, Forni G. Antitumor vaccines: is it possible to prevent a tumor? Cancer Immunol Immunother 2002;51:409-16.
12. Lozupone F, Rivoltini L, Lucani F, Venditti M, Lugini L, Cova A, Squarcina P, Parmiani G, Belardelli F, Fais S. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice. Eur J Immunol 2003;33:556-66.
13. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;311:999-1005.
14. Halevy O, Rodel J, Peled A, Oren M. Frequent p53 mutations in chemically induced murine fibrosarcoma. Oncogene 1991;6:1593-1600.
15. Shimokado K, Watanabe H, Sumii M, Miyagawa K, Kamiya K, Dohi K, Niwa O. p53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas. Jpn J Cancer Res 1998;89:269-77.
16. Vierboom MPM, Nijman HW, Offringa R, van der Voort EIH, van Hall T, van den Broek L, Fleuren G, Kenemans P, Kast WM, Melief CJM. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
17. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, Offringa R. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000;60:5508-13.
18. Lacabanne V, Viguier M, Guillet JG, Choppin J. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur J Immunol 1996;26:2635-9.
19. Hilburger Ryan M, Abrams SI. Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 2001;49:603-12.
20. Wojdani A, Alfred LJ. Alterations in cell-mediated immune functions induced in mouse splenic lymphocytes by polycyclic aromatic hydrocarbons. Cancer Res 1984;44:942-5.
21. Burchiel SW, Luster MI. Signaling by environmental polycyclic aromatic hydrocarbons in human lymphocytes. Clin Immunol 2001;98:2-10.
22. Lutz CT, Browne G, Petzold CR. Methylcholanthrene causes increased thymocyte apoptosis. Toxicology 1998;128:151-67.
23. Yamaguchi K, Near RI, Matulka RA, Shneider A, Toselli P, Trombino AF, Sherr DH. Activation of the aryl hydrocarbon receptor/transcription factor and bone marrow stromal cell-dependent preB cell apoptosis. J Immunol 1997;158:2165-73.
24. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, Kiessling R. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 1999;59:2950-6.
25. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999;48:346-52.
26. Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci USA 1994;91:3171-5.
27. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991;174:489-92.
28. Tuting T, Gambotto A, Robbins PD, Storkus WJ, DeLeo AB. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: Studies with the model tumor Ag-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999;6:629-36.
29. Tuting T, Gambotto A, De Leo AB, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1998;6:73-80.
30. DeLeo AB, Shiku H, Takahashi T, John M, Old LJ. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 1977;146:720-34.
31. Shu S, Chou T, Rosenberg SA. In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells. J Immunol 1986;136:3891-8.
32. Theobald M, Ruppert T, Kuckelkorn U, Hernandez J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C, Koszinowski UH, Kloetzel PM, et al. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 1998;188:1017-28.
33. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-41.
34. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside, TL, DeLeo, AB. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999;5:1281-8.
35. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside, TL, DeLeo AB. Generation of T cells specific for the wild-type sequence p53 (264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000;165:5938-44.
36. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immuno editing: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
37. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
38. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin Cancer Res 2003;9:641-9.
39. Urban JL, Holland JM, Kripke ML, Schreiber H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J Exp Med 1982;156:1025-41.
40. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F. Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 2001;91:109-19.
41. Crowe NY, Smyth MJ, Godfrey DI. A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 2002;196:119-27.